Toll Free: 1-888-928-9744
Toll Free: 1-888-928-9744
Published: Jul, 2016 | Pages:
45 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)
Momenta Pharmaceuticals, Inc. - Product Pipeline Review - 2016 Summary Global Markets Direct's, 'Momenta Pharmaceuticals, Inc. - Product Pipeline Review - 2016', provides an overview of the Momenta Pharmaceuticals, Inc.'s pharmaceutical research and development focus. The report provides comprehensive information on the therapeutics under development by Momenta Pharmaceuticals, Inc., complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and the dormant and discontinued projects. Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis. The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data. Scope - The report provides a snapshot of the pipeline therapeutic landscape of Momenta Pharmaceuticals, Inc. - The report provides overview of Momenta Pharmaceuticals, Inc. including its business description, key facts, and locations and subsidiaries - The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities - The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages - The report assesses Momenta Pharmaceuticals, Inc.'s pipeline therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type - The report features Momenta Pharmaceuticals, Inc.'s out-licensed and partnered product portfolio and summarizes its dormant and discontinued projects Reasons To Buy - Evaluate Momenta Pharmaceuticals, Inc.'s strategic position with total access to detailed information on its product pipeline - Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Identify and understand important and diverse types of therapeutics under development for Momenta Pharmaceuticals, Inc. - Identify potential new clients or partners in the target demographic - Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics - Devise corrective measures for pipeline projects by understanding Momenta Pharmaceuticals, Inc.'s pipeline depth and focus of pipeline therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
Table of Contents
Table of Contents 2 List of Tables 5 List of Figures 5 Momenta Pharmaceuticals, Inc. Snapshot 6 Momenta Pharmaceuticals, Inc. Overview 6 Key Information 6 Key Facts 6 Momenta Pharmaceuticals, Inc. - Research and Development Overview 7 Key Therapeutic Areas 7 Momenta Pharmaceuticals, Inc. - Pipeline Review 10 Pipeline Products by Stage of Development 10 Pipeline Products - Monotherapy 11 Momenta Pharmaceuticals, Inc. - Pipeline Products Glance 12 Momenta Pharmaceuticals, Inc. - Late Stage Pipeline Products 12 Phase III Products/Combination Treatment Modalities 12 Momenta Pharmaceuticals, Inc. - Clinical Stage Pipeline Products 13 Phase II Products/Combination Treatment Modalities 13 Phase I Products/Combination Treatment Modalities 14 Momenta Pharmaceuticals, Inc. - Early Stage Pipeline Products 15 Preclinical Products/Combination Treatment Modalities 15 Discovery Products/Combination Treatment Modalities 16 Momenta Pharmaceuticals, Inc. - Drug Profiles 17 adalimumab biosimilar 17 Product Description 17 Mechanism of Action 17 R&D Progress 17 necuparanib 18 Product Description 18 Mechanism of Action 18 R&D Progress 18 M-281 20 Product Description 20 Mechanism of Action 20 R&D Progress 20 abatacept biosimilar 21 Product Description 21 Mechanism of Action 21 R&D Progress 21 Antibody for Autoimmune Disorders and Inflammation 22 Product Description 22 Mechanism of Action 22 R&D Progress 22 M-230 23 Product Description 23 Mechanism of Action 23 R&D Progress 23 M-615 24 Product Description 24 Mechanism of Action 24 R&D Progress 24 M-706 25 Product Description 25 Mechanism of Action 25 R&D Progress 25 M-710 26 Product Description 26 Mechanism of Action 26 R&D Progress 26 M-730 27 Product Description 27 Mechanism of Action 27 R&D Progress 27 M-740 28 Product Description 28 Mechanism of Action 28 R&D Progress 28 Monoclonal Antibodies for Autoimmune Diseases 29 Product Description 29 Mechanism of Action 29 R&D Progress 29 Momenta Pharmaceuticals, Inc. - Pipeline Analysis 30 Momenta Pharmaceuticals, Inc. - Pipeline Products by Target 30 Momenta Pharmaceuticals, Inc. - Pipeline Products by Route of Administration 31 Momenta Pharmaceuticals, Inc. - Pipeline Products by Molecule Type 32 Momenta Pharmaceuticals, Inc. - Pipeline Products by Mechanism of Action 33 Momenta Pharmaceuticals, Inc. - Recent Pipeline Updates 34 Momenta Pharmaceuticals, Inc. - Dormant Projects 39 Momenta Pharmaceuticals, Inc. - Discontinued Pipeline Products 40 Discontinued Pipeline Product Profiles 40 bevacizumab biosimilar 40 Momenta Pharmaceuticals, Inc. - Company Statement 41 Momenta Pharmaceuticals, Inc. - Locations And Subsidiaries 43 Head Office 43 Other Locations & Subsidiaries 43 Appendix 44 Methodology 44 Coverage 44 Secondary Research 44 Primary Research 44 Expert Panel Validation 44 Contact Us 44 Disclaimer 45
List of Tables
Momenta Pharmaceuticals, Inc., Key Information 6 Momenta Pharmaceuticals, Inc., Key Facts 6 Momenta Pharmaceuticals, Inc. - Pipeline by Indication, 2016 8 Momenta Pharmaceuticals, Inc. - Pipeline by Stage of Development, 2016 10 Momenta Pharmaceuticals, Inc. - Monotherapy Products in Pipeline, 2016 11 Momenta Pharmaceuticals, Inc. - Phase III, 2016 12 Momenta Pharmaceuticals, Inc. - Phase II, 2016 13 Momenta Pharmaceuticals, Inc. - Phase I, 2016 14 Momenta Pharmaceuticals, Inc. - Preclinical, 2016 15 Momenta Pharmaceuticals, Inc. - Discovery, 2016 16 Momenta Pharmaceuticals, Inc. - Pipeline by Target, 2016 30 Momenta Pharmaceuticals, Inc. - Pipeline by Route of Administration, 2016 31 Momenta Pharmaceuticals, Inc. - Pipeline by Molecule Type, 2016 32 Momenta Pharmaceuticals, Inc. - Pipeline Products by Mechanism of Action, 2016 33 Momenta Pharmaceuticals, Inc. - Recent Pipeline Updates, 2016 34 Momenta Pharmaceuticals, Inc. - Dormant Developmental Projects,2016 39 Momenta Pharmaceuticals, Inc. - Discontinued Pipeline Products, 2016 40 Momenta Pharmaceuticals, Inc., Subsidiaries 43
Speak to the report author to design an exclusive study to serve your research needs.
Your personal and confidential information is safe and secure.
